Trial · NCT07884344
Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma
NCT07884344, Early phase 1, Recruiting, Macarena De La Fuente, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma. Trials, record NCT07884344. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884344
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma
- NCT number
- NCT07884344
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Macarena De La Fuente, MD
- Conditions
- Glioblastoma
- Interventions
- Lixumistat - Cohort 1, Lixumistat - Cohort 2
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Concentration of Lixumistat in Brain Tumor Tissue | Up to 6 months | Total concentration of lixumistat measured in brain tissue homogenate obtained from both contrast-enhancing and non-contrast-enhancing tumor regions. Total concentration of lixumistat in brain tissue homogenate will be reported in nanograms of analyte per milliliter of homogenate buffer, per milligram of tissue (ng/mL/mg). |
| Secondary | Pharmacodynamic (PD) Effects of Lixumistat in Brain Tumor Tissue | Up to 6 months | Pharmacodynamic (PD) effects of Lixumistat will be assessed by evaluating the Lixumistat-induced changes in the expression levels of mitochondrial Protein Complex I in brain tumor tissue obtained from study participants. PD analyses will be performed on tissue samples obtained from both contrast-enhancing and non-contrast-enhancing tumor regions. Lixumistat-induced changes in expression levels of mitochondrial Protein Complex I will be measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay from LabCorp. Expression levels of mitochondrial Protein Complex I will be reported as a fold change. |
| Secondary | Number of Participants Experiencing Treatment-Related Toxicity: Adverse Events (AEs) | Up to 6 months | The number of participants experiencing treatment-related adverse events (AEs) after starting protocol therapy will be reported. AEs will be evaluated using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
| Secondary | Number of Participants Experiencing Treatment-Related Toxicity: Serious Adverse Events (SAEs) | Up to 6 months | The number of participants experiencing treatment-related toxicity serious adverse events (SAEs) after starting protocol treatment will be reported. SAEs will be evaluated using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
| Secondary | Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | Up to 6 months | The number of participants experiencing dose-limiting toxicities (DLTs) after starting protocol therapy will be reported. DLTs will be evaluated using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884344
GET https://conductscience.org/api/trials/v1/NCT07884344/registered